Compare Stocks: RANI, QTTB, PRLD, and OCGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OCGN Ocugen	$1.32 -3.6%	$1.37	$1.00 ▼ $2.73	$447.63M	2.21	3.89 million shs	3.06 million shs
PRLD Prelude Therapeutics	$5.47 -13.7%	$4.94	$0.98 ▼ $6.83	$436.52M	0.96	496,097 shs	725,051 shs
QTTB Q32 Bio	$15.03 -6.9%	$14.90	$1.62 ▼ $23.57	$447.43M	0.23	423,652 shs	353,342 shs
RANI Rani Therapeutics	$0.84 -1.7%	$0.78	$0.44 ▼ $3.87	$117.09M	0.78	716,756 shs	371,367 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OCGN Ocugen	0.00%	-5.04%	+4.76%	-4.35%	+26.92%
PRLD Prelude Therapeutics	0.00%	-17.50%	+8.32%	+39.54%	+327.34%
QTTB Q32 Bio	0.00%	-5.89%	-3.41%	+36.02%	+773.84%
RANI Rani Therapeutics	0.00%	-4.55%	+2.40%	-11.65%	+49.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OCGN Ocugen	$1.32 -3.6%	$1.37	$1.00 ▼ $2.73	$447.63M	2.21	3.89 million shs	3.06 million shs
PRLD Prelude Therapeutics	$5.47 -13.7%	$4.94	$0.98 ▼ $6.83	$436.52M	0.96	496,097 shs	725,051 shs
QTTB Q32 Bio	$15.03 -6.9%	$14.90	$1.62 ▼ $23.57	$447.43M	0.23	423,652 shs	353,342 shs
RANI Rani Therapeutics	$0.84 -1.7%	$0.78	$0.44 ▼ $3.87	$117.09M	0.78	716,756 shs	371,367 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OCGN Ocugen	0.00%	-5.04%	+4.76%	-4.35%	+26.92%
PRLD Prelude Therapeutics	0.00%	-17.50%	+8.32%	+39.54%	+327.34%
QTTB Q32 Bio	0.00%	-5.89%	-3.41%	+36.02%	+773.84%
RANI Rani Therapeutics	0.00%	-4.55%	+2.40%	-11.65%	+49.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OCGN Ocugen	2.60	Moderate Buy	$9.50	619.70% Upside
PRLD Prelude Therapeutics	2.40	Hold	$7.67	40.16% Upside
QTTB Q32 Bio	2.71	Moderate Buy	$31.00	106.25% Upside
RANI Rani Therapeutics	2.83	Moderate Buy	$8.75	941.67% Upside

Current Analyst Ratings Breakdown

Latest RANI, QTTB, PRLD, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	RANI Rani Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	QTTB Q32 Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$34.00
8/21/2026	QTTB Q32 Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/21/2026	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	RANI Rani Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/11/2026	OCGN Ocugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	QTTB Q32 Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
7/29/2026	PRLD Prelude Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/28/2026	QTTB Q32 Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $36.00
7/17/2026	RANI Rani Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OCGN Ocugen	$4.41M	101.50	N/A	N/A	($0.05) per share	-26.40
PRLD Prelude Therapeutics	$12.14M	35.96	N/A	N/A	$1.68 per share	3.26
QTTB Q32 Bio	$53.74M	8.33	$1.52 per share	9.91	$3.56 per share	4.22
RANI Rani Therapeutics	$1.63M	71.84	N/A	N/A	$0.34 per share	2.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OCGN Ocugen	-$67.85M	-$0.26	N/A	N/A	N/A	N/A	-127,987.80%	-115.95%	11/4/2026 (Estimated)
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)
QTTB Q32 Bio	$29.82M	$3.00	5.01	N/A	N/A	N/A	50.17%	29.49%	11/12/2026 (Estimated)
RANI Rani Therapeutics	-$29.67M	-$0.27	N/A	N/A	N/A	N/A	-104.60%	-65.17%	11/5/2026 (Estimated)

Latest RANI, QTTB, PRLD, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	RANI Rani Therapeutics	-$0.05	-$0.04	+$0.01	-$0.04	$0.93 million	$1.71 million
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/6/2026	Q2 2026	OCGN Ocugen	-$0.0533	-$0.07	-$0.0167	-$0.07	$0.89 million	$1.49 million
8/5/2026	Q2 2026	QTTB Q32 Bio	-$0.46	-$0.44	+$0.02	-$0.44	$0.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OCGN Ocugen	4.17	0.80	0.80
PRLD Prelude Therapeutics	N/A	4.07	4.07
QTTB Q32 Bio	N/A	20.30	20.30
RANI Rani Therapeutics	N/A	5.31	5.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OCGN Ocugen	10.27%
PRLD Prelude Therapeutics	79.72%
QTTB Q32 Bio	31.32%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
OCGN Ocugen	3.95%
PRLD Prelude Therapeutics	49.20%
QTTB Q32 Bio	34.46%
RANI Rani Therapeutics	26.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OCGN Ocugen	80	339.11 million	325.72 million	Optionable
PRLD Prelude Therapeutics	120	79.80 million	40.54 million	Optionable
QTTB Q32 Bio	39	29.77 million	19.51 million	N/A
RANI Rani Therapeutics	110	139.40 million	102.14 million	Optionable

RANI, QTTB, PRLD, and OCGN Headlines

Recent News About These Companies

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 29 at 4:13 AM | marketbeat.com

Chardan Capital Upgrades Rani Therapeutics (NASDAQ:RANI) to Strong-Buy

August 28 at 7:29 AM | marketbeat.com

1,469,129 Shares in Rani Therapeutics Holdings, Inc. $RANI Purchased by Almitas Capital LLC

August 28 at 3:12 AM | marketbeat.com

Q4 EPS Estimate for Rani Therapeutics Decreased by Analyst

August 27 at 1:29 AM | americanbankingnews.com

AWM Investment Company Inc. Purchases Shares of 7,500,000 Rani Therapeutics Holdings, Inc. $RANI

August 26, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Sanofi (OtherSNYNF)

August 25, 2026 | theglobeandmail.com

HC Wainwright Issues Pessimistic Forecast for RANI Earnings

August 25, 2026 | marketbeat.com

Spruce Street Capital LP Buys New Stake in Rani Therapeutics Holdings, Inc. $RANI

August 25, 2026 | marketbeat.com

HC Wainwright Reiterates Buy Rating for Rani Therapeutics (NASDAQ:RANI)

August 23, 2026 | americanbankingnews.com

HC Wainwright Reaffirms "Buy" Rating for Rani Therapeutics (NASDAQ:RANI)

August 21, 2026 | marketbeat.com

Canaccord Genuity Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

August 20, 2026 | theglobeandmail.com

Rani Therapeutics (NASDAQ:RANI) Coverage Initiated at Chardan Capital

August 20, 2026 | americanbankingnews.com

Chardan Capital Initiates Coverage on Rani Therapeutics (NASDAQ:RANI)

August 18, 2026 | marketbeat.com

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

August 16, 2026 | marketbeat.com

Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS

August 13, 2026 | marketbeat.com

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

August 13, 2026 | globenewswire.com

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 10, 2026 | markets.businessinsider.com

Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair

August 4, 2026 | quiverquant.comQ

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Moderate Buy" from Analysts

August 4, 2026 | marketbeat.com

Rani Therapeutics (NASDAQ:RANI) CEO Talat Imran Sells 8,014 Shares of Stock

July 29, 2026 | insidertrades.com

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 20, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RANI, QTTB, PRLD, and OCGN Company Descriptions

Ocugen NASDAQ:OCGN

$1.32 -0.05 (-3.65%)

As of 08/28/2026 04:00 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Prelude Therapeutics NASDAQ:PRLD

$5.47 -0.87 (-13.72%)

As of 08/28/2026 04:00 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Q32 Bio NASDAQ:QTTB

$15.03 -1.12 (-6.93%)

As of 08/28/2026 04:00 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Rani Therapeutics NASDAQ:RANI

$0.84 -0.01 (-1.66%)

As of 08/28/2026 04:00 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RANI, QTTB, PRLD, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RANI, QTTB, PRLD, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RANI, QTTB, PRLD, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RANI, QTTB, PRLD, and OCGN Company Descriptions

Ocugen NASDAQ:OCGN

Prelude Therapeutics NASDAQ:PRLD

Q32 Bio NASDAQ:QTTB

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RANI, QTTB, PRLD, and OCGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RANI, QTTB, PRLD, and OCGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RANI, QTTB, PRLD, and OCGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RANI, QTTB, PRLD, and OCGN Company Descriptions

Ocugen NASDAQ:OCGN

Prelude Therapeutics NASDAQ:PRLD

Q32 Bio NASDAQ:QTTB

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools